Advate (octocog alfa)
- Region
- 🇪🇺 EU
- Active substance
- octocog alfa
- Company
- Takeda Manufacturing Austria AG
- Status
- Authorised
- Therapeutic area
- Hemophilia A
- EU approval
- Tue 02 Mar 2004
- Application
- EMEA/H/C/000520
- ATC
- B02BD02
- Official record
- www.ema.europa.eu
Indication
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). Advate does not contain von Willebrand factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Jivi Authorised · Bayer AG
- 🇪🇺 Afstyla Authorised · CSL Behring GmbH
- 🇪🇺 Altuvoct Authorised · Swedish Orphan Biovitrum AB (publ)
- 🇪🇺 Adynovi Authorised · Baxalta Innovations GmbH
- 🇪🇺 Elocta Authorised · Swedish Orphan Biovitrum AB (publ)
- 🇪🇺 Nuwiq Authorised · Octapharma AB
- 🇪🇺 Kovaltry Authorised · Bayer AG
- 🇪🇺 Obizur Authorised · Baxalta Innovations GmbH
- 🇪🇺 ReFacto AF Authorised · Pfizer Europe MA EEIG
- 🇪🇺 Esperoct Authorised · Novo Nordisk A/S
- 🇪🇺 Vihuma Authorised · Octapharma AB
- 🇪🇺 Kogenate Bayer Lapsed · Bayer AG
Follow Advate
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.